IXC

INVEX THER FPO [IXC]
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.
Healthcare · ASX Small Cap
$0.1050 -4.6%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when IXC triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IXC — Free

Active Signals

Bullish Signals

  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Volume surging at 16.2x normal while price falls — heavy selling pressure
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Strong cash runway (41 quarters)
  • 4C filed 2026-04-24
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.50%/day)
  • Liquidity risk: 10 zero-volume days in last 20
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 5d (+3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 31% over the past year
Ask Scout AI about IXC
"What's driving IXC today?" "How does IXC compare to peers?" "Key risks for IXC?"
3 free messages/day · Unlimited with Pro

Key Metrics

$7.9M
Market Cap
44K
Avg Volume
16.2x
Vol Ratio
$0.07 — $0.18
52-Week Range
N/A
Short Interest
20 qtrs
Cash Runway
-16.8%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 61%
LLeader vs LaggardlaggardRS: -12
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:IXC vs IDTIXC vs ADRIXC vs LDX
Scout Pro — Deeper Analysis for IXC
Try Pro free for 30 days
Share this analysis

Track IXC and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required